financetom
Business
financetom
/
Business
/
Eggs retailer Vital Farms beats Q2 revenue view; lifts FY outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eggs retailer Vital Farms beats Q2 revenue view; lifts FY outlook
Aug 7, 2025 4:49 AM

Overview

* Vital Farms ( VITL ) Q2 revenue rises 25.4% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q2 beats estimates, reflecting strategic pricing actions

* Co raises FY 2025 revenue outlook to at least $770 mln, up 27% from 2024

Outlook

* Vital Farms ( VITL ) raises fiscal 2025 net revenue outlook to at least $770 mln

* Company expects fiscal 2025 adjusted EBITDA of at least $110 mln

* Vital Farms ( VITL ) increases capital expenditure outlook to $90-110 mln

* Company anticipates margin pressure from tariffs and promotions in H2 2025

Result Drivers

* STRATEGIC PRICING - Price/mix benefits contributed $15.7 mln to revenue growth, per CEO Russell Diez-Canseco

* SUPPLY CHAIN EXPANSION - Expansion to 500 family farms and new production facilities supports increased revenue

* CONSUMER DEMAND - Accelerated demand for existing products and new offerings drove volume-related revenue growth of $21.7 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $184.77 $170.50

Revenue mln mln (10

Analysts

)

Q2 EPS $0.36

Q2 Net $16.64

Income mln

Q2 Beat $29.90 $22.70

Adjusted mln mln (9

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the food retail & distribution peer group is "buy"

* Wall Street's median 12-month price target for Vital Farms Inc ( VITL ) is $45.50, about 18% above its August 6 closing price of $37.30

* The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Wedbush Trims ONE Group Hospitality's PT to $5 From $6, Says 2024 Visibility Remains Limited; Maintains Neutral Rating
--Wedbush Trims ONE Group Hospitality's PT to $5 From $6, Says 2024 Visibility Remains Limited; Maintains Neutral Rating
Mar 18, 2024
07:15 AM EDT, 03/18/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) ...
Brazil's Embraer sees deliveries, revenue growing in 2024
Brazil's Embraer sees deliveries, revenue growing in 2024
Mar 18, 2024
SAO PAULO (Reuters) - Brazilian planemaker Embraer ( ERJ ) expects both its aircraft deliveries and revenues to grow in 2024, the company said on Monday. The world's third-largest planemaker behind Boeing ( BA ) and Airbus estimated it will deliver between 125 and 135 executive jets this year, compared with 115 in 2023. Deliveries from its commercial aviation segment...
Romanian nuclear project has $4 bln in U.S. financial support, says ambassador
Romanian nuclear project has $4 bln in U.S. financial support, says ambassador
Mar 18, 2024
DOICESTI, Romania, March 18 (Reuters) - A small modular nuclear reactor project in Romania has financial support worth $4 billion from United States Exim Bank and the United States International Development Finance Corporation, U.S. Ambassador Kathleen Ann Kavalec said on Monday. ...
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month
AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month
Mar 18, 2024
(Reuters) -AstraZeneca ( AZN ) said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move by rival Boehringer Ingelheim earlier this month. The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD),...
Copyright 2023-2026 - www.financetom.com All Rights Reserved